» Articles » PMID: 3450845

Concurrent Intravenous Administration of a Labeled Tracer to Determine the Oral Bioavailability of a Drug Exhibiting Michaelis-Menten Metabolism

Overview
Specialty Pharmacology
Date 1987 Dec 1
PMID 3450845
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The theoretical accuracy of concurrent administration of labeled intravenous tracer and oral doses to estimate the bioavailability of drugs exhibiting Michaelis-Menten kinetics was determined by computer simulation. The simulation model consisted of sampling and hepatic compartments with elimination occurring by hepatic metabolism according to the venous equilibration model. The relationships between error in bioavailability estimation and dose, metabolic activity (Vmax), first-order absorption rate constant (ka), and volume of distribution (V) and the fraction of the dose absorbed were examined. Error was hypothesized to be relatively low when conditions result in a relatively constant value of clearance after oral dosing or when the concentration-time curves after intravenous and oral dosing are similar. The results were consistent with these hypotheses and, under most conditions, error was less than 15%. The effects, on error, of altering the intravenous tracer dose input and having a lag time in absorption of drug from the oral dose were also determined. In general, accuracy was improved by delaying administration of the iv tracer for a time equal to 50% of the oral dose peak time or by administering the tracer dose by constant-rate infusion from the time of oral dosing to the peak time. Lag time in absorption of the oral dose was shown to often result in overestimates in bioavailability of greater than 50%.

Citing Articles

Preclinical Bioavailability Assessment of a Poorly Water-Soluble Drug, HGR4113, Using a Stable Isotope Tracer.

Ha E, Seo J, Rehman S, Park H, Yoo S, Hyun Yoo H Pharmaceutics. 2023; 15(6).

PMID: 37376132 PMC: 10305361. DOI: 10.3390/pharmaceutics15061684.


A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.

Schwab D, Portron A, Backholer Z, Lausecker B, Kawashima K Clin Pharmacokinet. 2013; 52(6):463-73.

PMID: 23494983 DOI: 10.1007/s40262-013-0051-z.


A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.

Wagner C, Simpson M, Zeitlinger M, Bauer M, Karch R, Abrahim A Clin Pharmacokinet. 2010; 50(2):111-20.

PMID: 21142292 PMC: 3763674. DOI: 10.2165/11537250-000000000-00000.


Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Sabnis S Vet Res Commun. 1999; 23(7):425-47.

PMID: 10598074 DOI: 10.1023/a:1006321625243.


Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

Semple H, Tam Y, Coutts R Pharm Res. 1990; 7(3):274-9.

PMID: 2339102 DOI: 10.1023/a:1015830330231.

References
1.
Strong J, Dutcher J, Lee W, Atkinson Jr A . Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther. 1975; 18(5 Pt 1):613-22. DOI: 10.1002/cpt1975185part1613. View

2.
Clements J, Heading R, Nimmo W, Prescott L . Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther. 1978; 24(4):420-31. DOI: 10.1002/cpt1978244420. View

3.
Eichelbaum M, Von Unruh G, Somogyi A . Application of stable labelled drugs in clinical pharmacokinetic investigations. Clin Pharmacokinet. 1982; 7(6):490-507. DOI: 10.2165/00003088-198207060-00002. View

4.
Mamada K, Kasuya Y, Baba S . Pharmacokinetic equivalence of deuterium-labeled and unlabeled phenytoin. Drug Metab Dispos. 1986; 14(4):509-11. View

5.
JENDEN D, Cho A . Selected ion monitoring in pharmacology. Biochem Pharmacol. 1979; 28(6):705-13. DOI: 10.1016/0006-2952(79)90345-9. View